# ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS

Study · id `cardio:ct-nct07371689` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07371689](<https://clinicaltrials.gov/study/NCT07371689>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07371689

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT07371689. Randomized; quadruple masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT07371689, source copy `cardio:ctgov-nct07371689-2026-01-28`, retrieved 2026-10-31)
- Planned start: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07371689, source copy `cardio:ctgov-nct07371689-2026-01-28`, retrieved 2026-10-31)
- Primary completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07371689, source copy `cardio:ctgov-nct07371689-2026-01-28`, retrieved 2026-10-31)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07371689, source copy `cardio:ctgov-nct07371689-2026-01-28`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT07371689, source copy `cardio:ctgov-nct07371689-2026-01-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07371689-2026-01-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS
- Acronym: ANAPEM
- Condition: PEDIATRIC ACUTE MYOCARDITIS
- Intervention (Drug): Anakinra, KINERET®
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 2625840336a392936866c2c62b95b42494961b19216805fda475b11c06720225
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
